BioLife Solns Raises FY24 Sales Guidance From $95.50M-$100M To $99M-$101M Vs. $105.79m
Portfolio Pulse from Benzinga Newsdesk
BioLife Solutions has raised its full-year 2024 sales guidance from $95.50M-$100M to $99M-$101M, although this is still below the expected $105.79M. The company also increased its Cell Processing revenue guidance to $70M-$71M.
August 08, 2024 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioLife Solutions has raised its FY24 sales guidance to $99M-$101M, which is an improvement but still below the expected $105.79M. The Cell Processing revenue guidance has also been increased to $70M-$71M.
The raised guidance indicates positive momentum for BioLife Solutions, although the new guidance is still below market expectations. This mixed signal may lead to a slight positive impact on the stock price as investors may focus on the improved outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100